Lonza has announced plans to invest CHF 500 million ($517 million) to construct a large-scale commercial drug-product fill–finish facility in Stein, Switzerland.

The new facility will be constructed in Stein on the same campus as Lonza’s current clinical drug-product facility. The facility is expected to be completed in 2026.

Lonza established drug-product development and manufacturing services in 2016 and has since expanded its clinical drug-product services in Switzerland (Basel, Stein, and Visp) and Guangzhou, China.

Source: Lonza